Data / Drug companies / Pfizer Laboratories Div Pfizer Inc
Pfizer Laboratories Div Pfizer Inc: 172 products in the FDA NDC directory, labeler code 0069
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Pfizer Laboratories Div Pfizer Inc (labeler code 0069) lists 172 products in the FDA National Drug Code Directory, covering 49 finished drugs by generic name. By type: 143 prescription drugs, 21 plasma derivatives. Its main marketing category is new drug applications (NDA). The newest product started marketing on August 27, 2026.
The request: Watch Pfizer Laboratories Div Pfizer Inc (FDA labeler code 0069): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0069
- Products in commercial distribution
- 172
- Packages
- 192
- Finished drugs by generic name
- 49
- Prescription products
- 143
- Over the counter products
- 0
- Flagged as original packager
- 113 of 113 products that carry the flag
- Started marketing in the last 12 months
- 5
- Products with a marketing end date set
- 19
- Earliest marketing start
- September 6, 1989
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 112 | 65.1% |
| Biologics (BLA) | 56 | 32.6% |
| Generic drugs (ANDA) | 3 | 1.7% |
| Unapproved drugs for a shortage | 1 | 0.6% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 143 | 83.1% |
| Plasma derivatives | 21 | 12.2% |
| Vaccines | 8 | 4.7% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Doxorubicin hydrochloride | 10 | 20 |
| Dalteparin sodium | 9 | 1 |
| Talazoparib | 9 | 2 |
| Immune globulin | 9 | 2 |
| Azithromycin dihydrate | 8 | 20 |
| Amlodipine and atorvastatin | 8 | 9 |
| Epoetin alfa-epbx | 7 | 2 |
| Palbociclib | 6 | 2 |
| Immune globulin intravenous (human) | 6 | 3 |
| Immunoglobulin g | 6 | 2 |
| Tofacitinib | 5 | 23 |
| Bosutinib | 5 | 5 |
| Nirmatrelvir and ritonavir | 5 | 1 |
| Crizotinib | 5 | 1 |
| Filgrastim-aafi | 4 | 1 |
| Sunitinib malate | 4 | 9 |
| Sildenafil citrate | 4 | 24 |
| Covid-19 vaccine, mrna | 4 | 2 |
| Abrocitinib | 3 | 2 |
| Amlodipine besylate | 3 | 49 |
| Propofol | 3 | 15 |
| Varenicline tartrate | 3 | 23 |
| Dacomitinib | 3 | 1 |
| Fosphenytoin sodium | 3 | 8 |
| Dofetilide | 3 | 12 |
| Marstacimab-hncq | 3 | 1 |
| Fesoterodine fumarate | 2 | 12 |
| Glasdegib | 2 | 1 |
| Nifedipine | 2 | 38 |
| Axitinib | 2 | 2 |
| Rituximab-pvvr | 2 | 1 |
| Bevacizumab-bvzr | 2 | 1 |
| Somatrogon-ghla | 2 | 1 |
| Lorlatinib | 2 | 2 |
| Trastuzumab-qyyp | 2 | 1 |
| Tick-borne encephalitis vaccine | 2 | 1 |
| Elranatamab-bcmm | 2 | 2 |
| Heparin sodium | 1 | 23 |
| Infliximab-dyyb | 1 | 2 |
| Tafamidis | 1 | 1 |
| Tafamidis meglumine | 1 | 1 |
| Ritlecitinib | 1 | 2 |
| Calcium folinate | 1 | 2 |
| Meningococcal groups a, b, c, w, and y vaccine | 1 | 1 |
| Zavegepant | 1 | 2 |
| Taliglucerase alfa | 1 | 1 |
| Pegfilgrastim-apgf | 1 | 1 |
| Etrasimod | 1 | 1 |
| Respiratory syncytial virus vaccine | 1 | 2 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 38 | 22.1% |
| Injection, solution | 36 | 20.9% |
| Solution | 22 | 12.8% |
| Capsule | 18 | 10.5% |
| Injection | 12 | 7% |
| Capsule, liquid filled | 8 | 4.7% |
| Kit | 8 | 4.7% |
| Tablet, film coated, extended release | 6 | 3.5% |
| Injection, powder, lyophilized, for solution | 6 | 3.5% |
| Tablet | 4 | 2.3% |
| Injection, suspension | 4 | 2.3% |
| Powder, for suspension | 3 | 1.7% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Comirnaty | 0069-2631 | Injection, suspension | Biologics (BLA) | August 27, 2026 |
| Comirnaty | 0069-2609 | Injection, suspension | Biologics (BLA) | August 27, 2026 |
| Hympavzi | 0069-0775 | Injection, solution | Biologics (BLA) | June 22, 2026 |
| Paxlovid | 0069-5450 | Kit | New drug applications (NDA) | January 5, 2026 |
| Lederle leucovorin | 0069-5886 | Tablet | Unapproved drugs for a shortage | December 18, 2025 |
| Hympavzi | 0069-1510 | Injection, solution | Biologics (BLA) | October 15, 2025 |
| Comirnaty | 0069-2528 | Injection, suspension | Biologics (BLA) | August 27, 2025 |
| Comirnaty | 0069-2501 | Injection, suspension | Biologics (BLA) | August 27, 2025 |
| Paxlovid | 0069-5434 | Kit | New drug applications (NDA) | July 9, 2025 |
| Paxlovid | 0069-5045 | Kit | New drug applications (NDA) | July 9, 2025 |
| Doxorubicin Hydrochloride | 0069-5629 | Injection, solution | New drug applications (NDA) | March 31, 2025 |
| Doxorubicin Hydrochloride | 0069-4031 | Injection, solution | New drug applications (NDA) | March 31, 2025 |
| Doxorubicin Hydrochloride | 0069-4205 | Injection, solution | New drug applications (NDA) | November 11, 2024 |
| Doxorubicin Hydrochloride | 0069-3358 | Injection, solution | New drug applications (NDA) | November 11, 2024 |
| Doxorubicin Hydrochloride | 0069-0343 | Injection, solution | New drug applications (NDA) | November 11, 2024 |
| Hympavzi | 0069-2151 | Injection, solution | Biologics (BLA) | November 5, 2024 |
| Doxorubicin Hydrochloride | 0069-1442 | Injection, solution | New drug applications (NDA) | October 14, 2024 |
| Doxorubicin Hydrochloride | 0069-0255 | Injection, solution | New drug applications (NDA) | October 14, 2024 |
| Doxorubicin Hydrochloride | 0069-0358 | Injection, solution | New drug applications (NDA) | August 19, 2024 |
| Doxorubicin Hydrochloride | 0069-0277 | Injection, solution | New drug applications (NDA) | August 19, 2024 |
| Abrysvo | 0069-2465 | Injection, powder, lyophilized, for solution | Biologics (BLA) | July 30, 2024 |
| Doxorubicin Hydrochloride | 0069-1542 | Injection, solution | New drug applications (NDA) | July 22, 2024 |
| Talzenna | 0069-0757 | Capsule, liquid filled | New drug applications (NDA) | April 17, 2024 |
| Talzenna | 0069-0655 | Capsule, liquid filled | New drug applications (NDA) | April 17, 2024 |
| Talzenna | 0069-0546 | Capsule, liquid filled | New drug applications (NDA) | April 17, 2024 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.